Lonza Group AG - Asset Resilience Ratio

Latest as of December 2024: 3.04%

Lonza Group AG (LONN) has an Asset Resilience Ratio of 3.04% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CHF600.00 Million

Cash + Short-term Investments

Total Assets

CHF19.73 Billion

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2004–2024)

This chart shows how Lonza Group AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Lonza Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF600.00 Million	3.04%
Total Liquid Assets	CHF600.00 Million	3.04%

Asset Resilience Insights

Limited Liquidity: Lonza Group AG maintains only 3.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Lonza Group AG Industry Peers by Asset Resilience Ratio

Compare Lonza Group AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Berry Genomics Co Ltd SHE:000710	Diagnostics & Research	0.45%
JOONGANG DNM Co.Ltd KQ:051980	Diagnostics & Research	27.26%
Predilife SA F:0GA	Diagnostics & Research	17.69%
GeneMatrix Inc KQ:109820	Diagnostics & Research	41.52%
Genoray Co. Ltd KQ:122310	Diagnostics & Research	0.03%
Green Cross Lab Cell Corporation KQ:144510	Diagnostics & Research	0.18%
Optipharm.CO.LTD KQ:153710	Diagnostics & Research	20.73%
Bionet TWO:1784	Diagnostics & Research	38.62%

Annual Asset Resilience Ratio for Lonza Group AG (2004–2024)

The table below shows the annual Asset Resilience Ratio data for Lonza Group AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	6.51%	CHF1.28 Billion	CHF19.73 Billion	-1.82pp
2023-12-31	8.33%	CHF1.40 Billion	CHF16.85 Billion	-3.15pp
2022-12-31	11.48%	CHF1.99 Billion	CHF17.36 Billion	-2.07pp
2021-12-31	13.55%	CHF2.23 Billion	CHF16.46 Billion	+13.84pp
2020-12-31	-0.29%	CHF-43.00 Million	CHF14.62 Billion	-0.03pp
2019-12-31	-0.27%	CHF-37.00 Million	CHF13.84 Billion	-0.71pp
2018-12-31	0.44%	CHF61.00 Million	CHF13.92 Billion	+0.23pp
2017-12-31	0.21%	CHF29.00 Million	CHF13.83 Billion	-0.73pp
2016-12-31	0.94%	CHF64.00 Million	CHF6.83 Billion	+0.89pp
2015-12-31	0.05%	CHF3.00 Million	CHF6.25 Billion	-0.09pp
2014-12-31	0.14%	CHF9.00 Million	CHF6.44 Billion	-0.27pp
2013-12-31	0.41%	CHF26.00 Million	CHF6.37 Billion	+1.58pp
2012-12-31	-1.17%	CHF-83.00 Million	CHF7.10 Billion	-0.37pp
2011-12-31	-0.80%	CHF-56.00 Million	CHF7.02 Billion	-0.82pp
2009-12-31	0.02%	CHF1.00 Million	CHF4.94 Billion	-0.06pp
2008-12-31	0.08%	CHF4.00 Million	CHF4.93 Billion	+0.65pp
2007-12-31	-0.57%	CHF-28.00 Million	CHF4.95 Billion	-0.26pp
2006-12-31	-0.31%	CHF-12.00 Million	CHF3.91 Billion	-0.03pp
2005-12-31	-0.28%	CHF-12.00 Million	CHF4.33 Billion	+0.05pp
2004-12-31	-0.33%	CHF-11.00 Million	CHF3.34 Billion	--

pp = percentage points

About Lonza Group AG

SW:LONN Switzerland Diagnostics & Research

Market Cap

$47.98 Billion

CHF37.95 Billion CHF

Market Cap Rank

#676 Global

#6 in Switzerland

Share Price

CHF543.40

Change (1 day)

+2.22%

52-Week Range

CHF467.40 - CHF599.80

All Time High

CHF769.70